A Phase 2 interventional study of Pazopanib followed by everolimus in Carcinoma, Renal Cell, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing pazopanib in Carcinoma, Renal Cell — 1 open to participants now, 4 under way, 1 of them phase 3. pazopanib · Carcinoma, Renal Cell.
Among the 45 studies testing pazopanib in Carcinoma, Renal Cell, this one is the 16th largest by enrollment, is one of 9 that started in 2012, is one of 21 in phase 2, and was the 25th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →1 of the 45 studies testing pazopanib in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 65+
By country, each count listing its studies:
pazopanib: first FDA approval 2009 (VOTRIENT), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 23 · Phase 3 7 · Phase 4 3
First in 2004; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 44 across the 45 interventional studies. Of the 38 that completed or were terminated, 18 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
38 studies in Carcinoma, Renal Cell by Novartis: none open now, 1 under way, none of them phase 3. Of 36 finished, 17 (47%) have results posted.
Among the 38 studies in Carcinoma, Renal Cell by Novartis, this one is the 23rd largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2012, is one of 12 in phase 2, and was the 21st registered.
Novartis’s Carcinoma, Renal Cell studies by the year they started, since 2001.
1 of the studies testing pazopanib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01684397Roswell Park Cancer InstitutePazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | 2027-02-20 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies testing pazopanib in Carcinoma, Renal Cell, from their registry updates:
Among Novartis’s 38 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma.
Due to changes in the RCC treatment landscape, info gained is no longer clinically relevant to patients. Data collected is deemed sufficient to meet objective.
A non-randomised, open label, single-arm phase II study to evaluate the efficacy and safety of 1st-line pazopanib followed by 2nd-line everolimus in patients with previously untreated advanced or metastatic renal cell carcinoma. Subjects received initial therapy with pazopanib followed, on progression, by 2nd-line therapy with everolimus. Study treatment - sequential treatment with pazopanib followed by everolimus - to continue until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional inclusion criteria for starting everolimus:
Exclusion Criteria:
Additional criteria for exclusion from the everolimus treatment period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First line pazopanib, followed by second line everolimus
Drug: Pazopanib followed by everolimus
Drug pages: Pazopanib · Everolimus
All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
Also known as: Pazopanib 1st line followed by everolimus 2nd line
Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST
Time between the date of first everolimus dose and date of disease progression or death (whichever comes first) in patients treated initially with pazopanib. Disease progression is measured by RECIST (Response Evaluation Criteria in Solid Tumors), which is at least a 20% increase in the sum of the target lesion longest diameters (LDs).
Time frame: Throughout the study period, up to 4 years
Progression Free Survival (PFS) Rates
PFS rates 3 and 6 months after date of first dose of second-line everolimus treatment.
Time frame: 3 months, 6 months
Objective Response Rate (ORR) for the Everolimus Treatment Period Using RECIST
Percentage of patients with Complete or Partial Response at any time following the start of second-line everolimus treatment as per RECIST. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.
Time frame: Throughout the study, up to 4 years
Objective Response Rate (ORR) for the Pazopanib Treatment Period Using RECIST
Percentage of patients with Complete or Partial Response at any time following the start of first-line pazopanib treatment. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.
Time frame: Throughout the study period, up to 4 years
Overall Survival of Everolimus (OSE)
Time from first everolimus dose until death due to any cause
Time frame: Throughout the study period, up to 4 years
Overall Survival From the Start (OSS) of Study Treatment
Time from first pazopanib dose until death due to any cause in patients who received at least one dose of pazopanib followed by everolimus
Time frame: Throughout the study, up to 4 years
PFS for the Pazopanib Treatment Period Using RECIST
Time from first pazopanib dose until disease progression or death from any cause (whichever occurred earlier), provided this occurred prior to the start of everolimus and within 6 months of last dose of pazopanib
Time frame: Throughout the study period, up to 4 years
A total of 74 patients were enrolled, all started first-line pazopanib treatment. Of these, 51 discontinued pazopanib and 38 continued to second-line everolimus treatment
| Milestone | Pazopanib | Everolimus |
|---|---|---|
| Started | 74 | 0 |
| Completed | 0 | 0 |
| Not completed | 74 | 0 |
| Withdrew: Disease progression | 51 | 0 |
| Withdrew: Adverse event | 19 | 0 |
| Withdrew: Other reason | 4 | 0 |
| Milestone | Pazopanib | Everolimus |
|---|---|---|
| Started | 0 | 38 |
| Completed | 0 | 0 |
| Not completed | 0 | 38 |
| Withdrew: Other reason | 0 | 7 |
| Withdrew: Disease progression | 0 | 25 |
| Withdrew: Adverse event | 0 | 6 |
Time between the date of first everolimus dose and date of disease progression or death (whichever comes first) in patients treated initially with pazopanib. Disease progression is measured by RECIST (Response Evaluation Criteria in Solid Tumors), which is at least a 20% increase in the sum of the target lesion longest diameters (LDs).
| months | Everolimus |
|---|---|
| Progression Free Survival (PFS) for the Everolimus Treatment Period Using RECIST | 5.1 (3.4 to 6.8) |
PFS rates 3 and 6 months after date of first dose of second-line everolimus treatment.
| Survival probability | All Patients |
|---|---|
| 3 months | 0.737 (0.554 to 0.854) |
| 6 months | 0.355 (0.196 to 0.517) |
Percentage of patients with Complete or Partial Response at any time following the start of second-line everolimus treatment as per RECIST. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.
| Percentages of Participants | All Patients |
|---|---|
| Complete response | 0.0 (0.00 to 9.3) |
| Partial response | 7.9 (1.7 to 21.4) |
Percentage of patients with Complete or Partial Response at any time following the start of first-line pazopanib treatment. RECIST Complete Response is defined to be a disappearance of all target lesion(s). RECIST Partial Response is defined to be at least a 30% decrease in the sum of the target lesion LDs.
| Percentages of participants | All Patients |
|---|---|
| Complete response | 6.8 (2.2 to 15.1) |
| Partial response | 39.2 (28.0 to 51.2) |
Time from first everolimus dose until death due to any cause
| months | Everolimus |
|---|---|
| Overall Survival of Everolimus (OSE) | 15.6 (9.9 to 25.3) |
Time from first pazopanib dose until death due to any cause in patients who received at least one dose of pazopanib followed by everolimus
| Months | Pazopanib |
|---|---|
| Overall Survival From the Start (OSS) of Study Treatment | 35.7 (26.7 to NA) |
Time from first pazopanib dose until disease progression or death from any cause (whichever occurred earlier), provided this occurred prior to the start of everolimus and within 6 months of last dose of pazopanib
| Months | Pazopanib |
|---|---|
| PFS for the Pazopanib Treatment Period Using RECIST | 11.0 (7.2 to 14.8) |
Collected over Adverse events for each intervention were assessed from the time of first dose of treatment to approximately one month after discontinuation of the last dose of treatment, up to 4 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pazopanib | 5/74 (6.8%) | 47/74 (63.5%) | 73/74 (98.6%) |
| Everolimus | 3/38 (7.9%) | 16/38 (42.1%) | 34/38 (89.5%) |
| Event | Pazopanib | Everolimus |
|---|---|---|
| PneumoniaInfections and infestations | 2/74 | 4/38 |
| Alanine Aminotransferase IncreasedInvestigations | 6/74 | 0/38 |
| Mucosal InflammationGeneral disorders | 0/74 | 2/38 |
| VomitingGastrointestinal disorders | 2/74 | 0/38 |
| GastroenteritisInfections and infestations | 2/74 | 0/38 |
| Back PainMusculoskeletal and connective tissue disorders | 2/74 | 0/38 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/74 | 0/38 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/74 | 1/38 |
| AnaemiaBlood and lymphatic system disorders | 1/74 | 1/38 |
| DuodenitisGastrointestinal disorders | 0/74 | 1/38 |
| Event | Pazopanib | Everolimus |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 45/74 | 1/38 |
| FatigueGeneral disorders | 44/74 | 4/38 |
| NauseaGastrointestinal disorders | 37/74 | 6/38 |
| HypertensionVascular disorders | 24/74 | 0/38 |
| Decreased AppetiteMetabolism and nutrition disorders | 20/74 | 5/38 |
| DysgeusiaNervous system disorders | 18/74 | 2/38 |
| AnaemiaBlood and lymphatic system disorders | 3/74 | 9/38 |
| VomitingGastrointestinal disorders | 17/74 | 5/38 |
| Hair Colour ChangesSkin and subcutaneous tissue disorders | 17/74 | 0/38 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/74 | 7/38 |
All Treated Subjects (ATS) population included all patients who received at least one dose of pazopanib.
| Age, Continuous(Years) | All Patients |
|---|---|
| Mean | 66.0 ± 10.68 |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 20 |
| Male | 54 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Apr 2012 to primary completion in Nov 2016, 54 months.
Results were first posted in Oct 2019, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pazopanib · Everolimus